JP2001261580A - Medicine of dissolution type in time of use - Google Patents
Medicine of dissolution type in time of useInfo
- Publication number
- JP2001261580A JP2001261580A JP2000070637A JP2000070637A JP2001261580A JP 2001261580 A JP2001261580 A JP 2001261580A JP 2000070637 A JP2000070637 A JP 2000070637A JP 2000070637 A JP2000070637 A JP 2000070637A JP 2001261580 A JP2001261580 A JP 2001261580A
- Authority
- JP
- Japan
- Prior art keywords
- starch
- medicine
- cold
- time
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000004090 dissolution Methods 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920002472 Starch Polymers 0.000 claims abstract description 25
- 235000019698 starch Nutrition 0.000 claims abstract description 24
- 239000008107 starch Substances 0.000 claims abstract description 24
- 229940124579 cold medicine Drugs 0.000 claims description 22
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 229920001592 potato starch Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010013911 Dysgeusia Diseases 0.000 abstract description 8
- 239000000796 flavoring agent Substances 0.000 abstract description 8
- 235000019634 flavors Nutrition 0.000 abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 229960000920 dihydrocodeine Drugs 0.000 description 3
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- -1 rice starch Polymers 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、用時溶解型医薬、
とりわけ、用時溶解型風邪薬、いわゆる、溶かして飲む
風邪薬に関する。より詳細には、服用時にお湯や水に溶
かして服用した際の風味、コク、後味などの服用感が向
上された風邪薬に関する。TECHNICAL FIELD [0001] The present invention relates to a time-dissolved drug,
In particular, the present invention relates to a cold medicine for use at the time of use, that is, a so-called cold medicine for drinking. More specifically, the present invention relates to a cold medicine having an improved flavor, richness, and aftertaste when taken after being dissolved in hot water or water when taken.
【0002】[0002]
【従来の技術】生活者ニーズが多様化している現代にお
いては、これに対応した製品開発が望まれている。この
ような観点から、近年、風邪薬についても、従来の散
剤、顆粒剤、錠剤、カプセル剤などの固形製剤の形態と
して服用するものとは異なった、用時溶解型製剤、すな
わち、服用時にお湯や水に溶かして服用する製剤が開発
され、すでに市販されている。用時溶解型風邪薬は、錠
剤などの固形製剤の服用が苦手な人にマッチした風邪薬
であり、お湯で溶かして服用すれば、風邪薬本来の効果
が得られるとともに、身体を暖める効果や、発熱などで
失われた水分を補給する効果などが得られる点において
優れている。用時溶解型風邪薬は、液状にて服用される
風邪薬であるので、風邪薬本来の効果が得られなければ
ならないことは当然のことながら、服用した際の風味、
コク、後味などの服用感が重要な要素となる。風邪薬に
含まれる有効成分には苦味の強い成分が多いので、現在
市販されている用時溶解型風邪薬は、甘味成分や酸味成
分を配合してレモン味などにすることにより、風味の点
では服用しやすい製剤化がなされている。2. Description of the Related Art In today's world in which the needs of consumers are diversifying, it is desired to develop products corresponding to this. From such a viewpoint, in recent years, cold medicines are also different from conventional medicines, granules, tablets, capsules and the like which are taken in the form of solid preparations. Formulations that can be taken in water or in water have been developed and are already on the market. Cold-acting cold medicines are cold medicines that are suitable for people who are not good at taking solid preparations such as tablets.If they are dissolved in hot water and taken, they will not only have the cold medicine's original effect, but also have the effect of warming the body. It is excellent in that the effect of replenishing water lost due to heat generation is obtained. Since the cold medicine for use is a cold medicine that is taken in a liquid state, it is natural that the original effect of the cold medicine must be obtained.
The feeling of taking such as body and aftertaste is an important factor. Many of the active ingredients contained in cold medicines have strong bitterness.Currently available cold-melting cold medicines are prepared by adding sweet and sour ingredients to make them lemon-like. Has been formulated to be easy to take.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、風味が
よくてもコクや後味などを含めた全体的な服用感が優れ
ていなければ誰もが服用しやすいものとは言えず、風味
以外の服用感については、現在市販されている用時溶解
型風邪薬は、改善の余地を残しているのが実情である。
そこで、本発明は、服用時にお湯や水に溶かして服用し
た際の風味、コク、後味などの服用感が向上された用時
溶解型風邪薬などの用時溶解型医薬を提供することを目
的とする。However, even if the flavor is good, it is not easy for anyone to take it unless the overall feeling of taking, including the richness and aftertaste, is excellent. As for, the currently available cold-dissolving cold medicines still have room for improvement.
Therefore, an object of the present invention is to provide a time-dissolved medicine such as a cold-dissolved cold medicine with an improved feeling of taking such as flavor, body, aftertaste when dissolved and taken in hot water or water when taken. And
【0004】[0004]
【課題を解決するための手段】本発明者らは、上記の点
に鑑み、添加剤を用時溶解型風邪薬に配合することで服
用感の向上を図ることを検討した結果、添加剤としてデ
ンプンを配合すると、風味、コク、後味などを含めた全
体的な服用感が向上し、デンプンを配合しない製剤と比
較してより服用しやすい製剤となることを見出した。Means for Solving the Problems In view of the above points, the present inventors have studied to improve the feeling of ingestion by adding an additive to a cold medicine for use at the time of use. It has been found that when starch is blended, the overall feeling of taking, including flavor, richness, aftertaste, etc., is improved, and the formulation is easier to take than a formulation without starch.
【0005】本発明は、上記の知見に基づいてなされた
ものであり、本発明の用時溶解型医薬は、請求項1記載
の通り、デンプンを配合することを特徴とする。また、
請求項2記載の用時溶解型医薬は、請求項1記載の用時
溶解型医薬において、医薬が風邪薬であることを特徴と
する。また、請求項3記載の用時溶解型医薬は、請求項
1または2記載の用時溶解型医薬において、デンプンが
トウモロコシデンプンおよび/またはバレイショデンプ
ンであることを特徴とする。また、請求項4記載の用時
溶解型医薬は、請求項1乃至3のいずれかに記載の用時
溶解型医薬において、溶解に用いるお湯または水1重量
部に対してデンプンが0.0001重量部〜0.1重量
部となるように配合することを特徴とする。また、本発
明の用時溶解型医薬の服用感向上方法は、請求項5記載
の通り、デンプンを配合することを特徴とする。[0005] The present invention has been made based on the above findings, and the time-dissolved drug of the present invention is characterized by incorporating starch as described in claim 1. Also,
According to a second aspect of the present invention, there is provided a freshly-dissolved medicine according to the first aspect, wherein the medicine is a cold medicine. In addition, the freshly-dissolved medicine according to claim 3 is characterized in that, in the freshly-dissolved medicine according to claim 1 or 2, the starch is corn starch and / or potato starch. In addition, the ready-to-use medicine according to claim 4 is the same as in any of claims 1 to 3, except that the starch is 0.0001% by weight based on 1 part by weight of hot water or water used for dissolution. Parts to 0.1 parts by weight. Further, the method for improving the feeling of taking a ready-to-use drug of the present invention is characterized in that starch is blended as described in claim 5.
【0006】[0006]
【発明の実施の形態】本発明において用時溶解型医薬に
配合されるデンプンとしては、トウモロコシデンプン、
バレイショデンプン、コメデンプン、コムギデンプンな
ど、植物の同化デンプンの他、これらの加工品であるヒ
ドロキシプロピルスターチ、アルファー化デンプン、部
分アルファー化デンプンなどの食用加工デンプンなどが
挙げられるが、服用した際の風味をより向上させるため
にはトウモロコシデンプンおよび/またはバレイショデ
ンプンを配合することが望ましい。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, corn starch, corn starch,
Potato starch, rice starch, wheat starch, and the like, as well as assimilable starch of plants, these processed products such as hydroxypropyl starch, pregelatinized starch, edible processed starch such as partially pregelatinized starch, and the like. In order to further improve the flavor, it is desirable to add corn starch and / or potato starch.
【0007】用時溶解型医薬に配合するデンプンの量
は、医薬に含まれる成分や含量に応じて適宜調整される
ものであるが、一般的には、溶解に用いるお湯または水
1重量部に対してデンプンが0.0001重量部〜0.
1重量部、望ましくは、0.0003重量部〜0.01
重量部となるように配合することが望ましい。デンプン
の配合量が0.0001重量部より少ない場合は、その
効果が十分に発揮されない恐れがある一方、0.1重量
部より多い場合は、とろみが強くなりすぎて、ほどよい
服用感が得られなくなる恐れがあるからである。[0007] The amount of starch to be added to the dissolving drug at the time of use is appropriately adjusted in accordance with the components and content contained in the drug. Generally, the amount of starch is 1 part by weight of hot water or water used for dissolution. On the other hand, the amount of starch is 0.0001 parts by weight to 0.
1 part by weight, desirably 0.0003 parts by weight to 0.01
It is desirable to mix them in parts by weight. When the amount of the starch is less than 0.0001 part by weight, the effect may not be sufficiently exhibited. On the other hand, when the amount is more than 0.1 part by weight, the thickening becomes too strong, and a moderate feeling of taking is obtained. This is because they may not be able to do so.
【0008】本発明を適用することができる用時溶解型
医薬は、服用時にお湯や水に溶かして服用する医薬であ
れば特に限定されるものではなく、例えば、用時溶解型
風邪薬が挙げられる。[0008] The time-dissolved drug to which the present invention can be applied is not particularly limited as long as it is a drug which is dissolved in hot water or water when taken, and examples thereof include a cold-dissolved cold drug. Can be
【0009】用時溶解型風邪薬とは、服用時にお湯や水
に溶かして服用される風邪薬であり、風邪の諸症状(の
どの痛み、せき、悪寒、発熱、頭痛、鼻水、鼻づまり、
くしゃみ、たん、関節の痛み、筋肉の痛み)の緩和の効
能を謳う製剤を意味する。溶解に用いるお湯や水の量
は、一般的には11mL以上である。なお、本発明にお
いて使用される「溶かす」および「溶解」なる用語は、
その結果物が完全に溶液化するものの他、一部の成分が
溶解せずに分散化するものや懸濁化するものも含むもの
とする。[0009] The cold medicine for use is a cold medicine which is taken by dissolving it in hot water or water at the time of taking it, and having various symptoms of a cold (throat pain, cough, chills, fever, headache, runny nose, stuffy nose,
It means a preparation that claims to relieve sneezing, sputum, joint pain and muscle pain). The amount of hot water or water used for dissolution is generally 11 mL or more. The terms “dissolve” and “dissolve” used in the present invention are defined as
In addition to those that result in a complete solution, those that disperse or suspend some of the components without dissolving are also included.
【0010】用時溶解型風邪薬の有効成分としては、ア
セトアミノフェンなどの解熱鎮痛成分を必須成分とし、
解熱鎮痛成分と共に、マレイン酸クロルフェニラミンな
どの抗ヒスタミン成分、リン酸ジヒドロコデインや臭化
水素酸デキストロメトルファンなどの鎮咳成分、塩酸メ
チルエフェドリンなどの気管支拡張成分、グアヤコール
スルホン酸カリウムなどの去痰成分、カフェイン類、ビ
タミンCなどのビタミン類、合成ケイ酸アルミニウムな
どの制酸剤、甘草などの生薬成分の他、漢方処方などが
適宜配合される。[0010] As an active ingredient of the cold-dissolving cold medicine, an antipyretic analgesic ingredient such as acetaminophen is an essential ingredient,
Along with antipyretic analgesic components, antihistamine components such as chlorpheniramine maleate, antitussive components such as dihydrocodeine phosphate and dextromethorphan hydrobromide, bronchodilator components such as methylephedrine hydrochloride, expectorant components such as potassium guaiacol sulfonate, In addition to caffeine, vitamins such as vitamin C, antacids such as synthetic aluminum silicate, crude drug components such as licorice, a Chinese herbal prescription and the like are appropriately blended.
【0011】また、その風味を向上させるために、白糖
やアスパルテームやステビアなどの甘味成分やクエン酸
などの酸味成分が適宜配合される。In order to improve the flavor, a sweet component such as sucrose, aspartame and stevia, and an acid component such as citric acid are appropriately added.
【0012】本発明における用時溶解型医薬の剤型とし
ては、散剤、顆粒剤、発泡錠などが挙げられ、これら
は、ポビドンなどの結合剤や軽質無水ケイ酸などの分散
剤などを添加剤として適宜配合した上で、自体周知の方
法により製剤化される。なお、製剤中のデンプン配合量
は、0.1質量%〜30質量%、望ましくは0.5質量
%〜5質量%とすることが望ましい。Examples of the dosage form of the ready-to-use drug in the present invention include powders, granules, effervescent tablets and the like. These include additives such as a binder such as povidone and a dispersant such as light silicic anhydride. And then formulated by a method known per se. The amount of starch in the preparation is preferably 0.1% by mass to 30% by mass, more preferably 0.5% by mass to 5% by mass.
【0013】[0013]
【実施例】以下、本発明の用時溶解型医薬を用時溶解型
風邪薬を例にとって詳細に説明するが、本発明は以下の
記載に何ら制限されるものではない。 実施例1:デンプンとしてトウモロコシデンプンを用
い、以下の成分を秤量し、均一に混合した後、精製水を
用いて湿式造粒を行い、乾燥して散剤とした。得られた
散剤を分包して本発明の用時溶解型風邪薬である分包剤
3包を得た(1包当たり5g)。 アセトアミノフェン 900.0mg dl−マレイン酸クロルフェニラミン 7.5mg リン酸ジヒドロコデイン 24.0mg dl−塩酸メチルエフェドリン 60.0mg 無水カフェイン 75.0mg アスコルビン酸 500.0mg 白糖 11638.5mg アスパルテーム 90.0mg ステビア 15.0mg クエン酸 750.0mg ポビドン(K30) 600.0mg トウモロコシデンプン 300.0mg 軽質無水ケイ酸 40.0mgEXAMPLES The in-use medicine of the present invention will be described in detail below with reference to an in-use cold medicine, but the invention is not limited to the following description. Example 1: Corn starch was used as a starch, and the following components were weighed and uniformly mixed. Then, wet granulation was performed using purified water, followed by drying to obtain a powder. The obtained powder was packaged to obtain 3 packets of a packaged medicine which is a cold solution for use according to the present invention (5 g per package). Acetaminophen 900.0 mg dl-chlorpheniramine maleate 7.5 mg dihydrocodeine phosphate 24.0 mg dl-methylephedrine hydrochloride 60.0 mg anhydrous caffeine 75.0 mg ascorbic acid 500.0 mg white sugar 11638.5 mg aspartame 90.0 mg stevia 15.0 mg citric acid 750.0 mg povidone (K30) 600.0 mg corn starch 300.0 mg light silicic anhydride 40.0 mg
【0014】比較例1:以下の成分を秤量し、均一に混
合した後、精製水を用いて湿式造粒を行い、乾燥して散
剤とし、これを分包して分包剤3包を得た(1包当たり
5g)。 アセトアミノフェン 900.0mg dl−マレイン酸クロルフェニラミン 7.5mg リン酸ジヒドロコデイン 24.0mg dl−塩酸メチルエフェドリン 60.0mg 無水カフェイン 75.0mg アスコルビン酸 500.0mg 白糖 11938.5mg アスパルテーム 90.0mg ステビア 15.0mg クエン酸 750.0mg ポビドン(K30) 600.0mg 軽質無水ケイ酸 40.0mgComparative Example 1: After weighing and uniformly mixing the following components, wet granulation was performed using purified water, and dried to form a powder, which was packaged to obtain three packages. (5 g per packet). Acetaminophen 900.0 mg dl-chlorpheniramine maleate 7.5 mg dihydrocodeine phosphate 24.0 mg dl-methylephedrine hydrochloride 60.0 mg caffeine anhydrous 75.0 mg ascorbic acid 500.0 mg sucrose 11938.5 mg aspartame 90.0 mg stevia 15.0mg Citric acid 750.0mg Povidone (K30) 600.0mg Light silicic anhydride 40.0mg
【0015】試験例1: (試験材料)試験材料として、デンプンを配合した実施
例1の製剤(試料A)とデンプンを配合していない比較
例1の製剤(試料B)を用いた。 (試験方法)20歳代〜50歳代の健常成人男女合計3
0名をパネラーとして服用感に関するアンケート調査を
行った。アンケート調査は、パネラーが試料Aと試料
B、各1包をそれぞれお湯100mLに溶解させて服用
した後、アンケート用紙に回答する方法を用いた。評価
項目は、甘味酸味苦味コク後味おいしさ
総合評価の7項目とし、これらを非常に良い、良い、比
較的良い、どちらでもない、比較的悪い、悪い、非常に
悪いの7段階で評価して判定を行った。なお、パネラー
には試料の中身を明かさずクロスオーバーで服用しても
らった。 (試験結果)各パネラーの各評価項目についてのアンケ
ート結果を点数化し、全パネラーにおける平均点を求め
た。結果を表1に示す。また、この平均点をグラフ化し
た結果を図1に示す。表1および図1から明らかなよう
に、全評価項目について、実施例1のデンプンを配合し
た試料Aが比較例1のデンプンを配合していない試料B
に比較して高い数値を示し、良好な評価であった。中で
もコクについての評価が優れていた。Test Example 1: (Test Materials) As the test materials, the formulation of Example 1 containing the starch (Sample A) and the formulation of Comparative Example 1 containing no starch (Sample B) were used. (Test method) Total of 3 healthy adult men and women in their 20s to 50s
A questionnaire survey regarding the feeling of taking was conducted with 0 panelists. In the questionnaire survey, a method in which a paneler dissolves sample A and sample B, one packet each in 100 mL of hot water, and takes them, and then responds to a questionnaire sheet was used. The evaluation items were seven items of comprehensive evaluation of sweetness, sourness, bitterness, aftertaste and taste, and evaluated on a seven-point scale of very good, good, relatively good, neither, relatively bad, bad, and very bad. The judgment was made. In addition, the panelists were asked to take the sample in a crossover without revealing the contents of the sample. (Test Results) The questionnaire results for each evaluation item of each panel were scored, and the average score of all panelists was obtained. Table 1 shows the results. FIG. 1 shows the result of graphing the average points. As is clear from Table 1 and FIG. 1, for all the evaluation items, the sample A containing the starch of Example 1 was the same as the sample B not containing the starch of Comparative Example 1.
The value was higher than that of the sample, and the evaluation was good. Among them, the evaluation of the body was excellent.
【0016】[0016]
【表1】 [Table 1]
【0017】[0017]
【発明の効果】本発明によれば、用時溶解型風邪医薬に
デンプンを配合することにより、服用時にお湯や水に溶
かして服用した際の風味、コク、後味などの服用感を向
上させることができる。According to the present invention, it is possible to improve the feeling of taking, such as the flavor, richness, and aftertaste, when the medicine is taken by dissolving in hot water or water at the time of taking by taking starch into the cold medicine at the time of use. Can be.
【図1】 実施例1の試料Aと比較例1の試料Bの服用
感に関する評価結果を示すグラフ。FIG. 1 is a graph showing the evaluation results regarding the feeling of taking a sample A of Example 1 and a sample B of Comparative Example 1.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 安藤 伸治 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 Fターム(参考) 4C076 AA30 BB01 CC04 DD29 DD38 DD43 DD59 DD60 DD69 EE16 EE38 EE41 FF06 FF15 4C084 AA17 MA52 NA04 NA09 NA10 ZA071 ZA072 ZA081 ZA082 4C206 AA01 GA31 KA01 MA02 MA05 MA72 NA04 NA09 NA10 ZA07 ZA08 ────────────────────────────────────────────────── ─── Continuing on the front page (72) Inventor Shinji Ando 3-24-1, Takada, Toshima-ku, Tokyo Taisho Seiyaku Co., Ltd. F-term (reference) 4C076 AA30 BB01 CC04 DD29 DD38 DD43 DD59 DD60 DD69 EE16 EE38 EE41 FF06 FF15 4C084 AA17 MA52 NA04 NA09 NA10 ZA071 ZA072 ZA081 ZA082 4C206 AA01 GA31 KA01 MA02 MA05 MA72 NA04 NA09 NA10 ZA07 ZA08
Claims (5)
時溶解型医薬。(1) A pre-dissolution type medicine characterized by blending starch.
求項1記載の用時溶解型医薬。2. The pharmacologically soluble medicine according to claim 1, wherein the medicine is a cold medicine.
/またはバレイショデンプンであることを特徴とする請
求項1または2記載の用時溶解型医薬。3. The pharmaceutical composition according to claim 1, wherein the starch is corn starch and / or potato starch.
してデンプンが0.0001重量部〜0.1重量部とな
るように配合することを特徴とする請求項1乃至3のい
ずれかに記載の用時溶解型医薬。4. The method according to claim 1, wherein the starch is blended in an amount of 0.0001 to 0.1 parts by weight with respect to 1 part by weight of hot water or water used for dissolution. The pharmacologically soluble drug according to the above.
時溶解型医薬の服用感向上方法。5. A method for improving the feeling of taking a ready-to-dissolve drug, which comprises mixing starch.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000070637A JP2001261580A (en) | 2000-03-14 | 2000-03-14 | Medicine of dissolution type in time of use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000070637A JP2001261580A (en) | 2000-03-14 | 2000-03-14 | Medicine of dissolution type in time of use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001261580A true JP2001261580A (en) | 2001-09-26 |
Family
ID=18589344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000070637A Withdrawn JP2001261580A (en) | 2000-03-14 | 2000-03-14 | Medicine of dissolution type in time of use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2001261580A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003213300A (en) * | 2001-11-23 | 2003-07-30 | Rohm & Haas Co | Optimized pellet formulation |
US9078824B2 (en) | 2007-09-24 | 2015-07-14 | The Procter & Gamble Company | Composition and method of stabilized sensitive ingredient |
-
2000
- 2000-03-14 JP JP2000070637A patent/JP2001261580A/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003213300A (en) * | 2001-11-23 | 2003-07-30 | Rohm & Haas Co | Optimized pellet formulation |
US9078824B2 (en) | 2007-09-24 | 2015-07-14 | The Procter & Gamble Company | Composition and method of stabilized sensitive ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2874967B2 (en) | Pharmaceutical water suspension for drug actives essentially insoluble in water | |
EP3193887A1 (en) | Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions | |
US20160250336A1 (en) | Chinese herb medicine composition in the form of jelly | |
US5626879A (en) | Terfenadine oral granules | |
JP4190769B2 (en) | Oral liquid composition | |
JP2002193839A (en) | Cocoa pharmaceutical preparation | |
JP4373649B2 (en) | Oral solution | |
JP2001010977A (en) | Composition for oral administration | |
JP2001261580A (en) | Medicine of dissolution type in time of use | |
JP2001509175A (en) | A taste-masking composition for pharmaceuticals that is tasteless and unpalatable | |
JP2001294524A (en) | Solid pharmaceutical preparation for internal use comprising acetaminophen formulated therein | |
JP5070669B2 (en) | Oral gel preparation with improved antiseptic properties | |
JP6565334B2 (en) | Solid preparation | |
JP7499026B2 (en) | Internal pharmaceutical composition | |
JPH1036252A (en) | Oral liquid medicine combined with belladonna (total) alkaloid | |
JPH10101582A (en) | Oral cavity solution type solid preparation | |
JPH085784B2 (en) | Syrup | |
CN106580886A (en) | Diclofenac potassium powder and preparation method thereof | |
JPH0952829A (en) | Muscle relaxant | |
JPH0952849A (en) | Composition for cold remedy | |
JP2004099559A (en) | Jelly formulation for pharmaceutical use | |
JPH0977675A (en) | Crude drug-formulated foaming tablet | |
JP2001253826A (en) | Internal medicine | |
KR20000065822A (en) | Icecream-type Pharmaceutical Formulation and Process for Preparing the Same | |
JP2001106641A (en) | Intraoral medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20070605 |